Neurocrine Biosciences Inc (NBIX)

Name: Neurocrine Biosciences Inc (NBIX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name NEUROCRINE BIOSCIENCES INC · CIK 0000914475 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Neurocrine Biosciences Inc reported revenue of $2.86B. Revenue grew 21.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.37B.

Key ratios (year ended 2025-12-31)

21.6%

Operating margin

16.7%

Net margin

14.7%

Return on year-end equity

21.4%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-28

Headquarters locality: San Diego · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$3.37B	$2.86B	$2.36B	$1.89B	$1.49B	$1.13B	$1.05B	$788.10M	$451.20M	$161.63M	$15.00M
Cost of Revenue	n/a	$52.10M	$34.00M	$39.70M	$23.20M	$14.30M	$10.10M	n/a	$4.89M	$1.25M	$0
R&D Expense	$1.13B	$1.02B	$731.10M	$565.00M	$463.80M	$328.10M	$275.00M	n/a	n/a	n/a	n/a
Operating Income	$794.80M	$619.10M	$570.50M	$250.90M	$249.00M	$102.50M	$163.00M	$72.30M	$36.80M	-$131.36M	-$147.37M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$4.02M	$2.40M	$1.45M
EBITDA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$40.82M	-$128.96M	-$145.92M
Net Income	$705.50M	$478.60M	$341.30M	$249.70M	$154.50M	$89.60M	$407.30M	$37.00M	$21.10M	-$142.54M	-$141.09M
EPS (Diluted)	n/a	$4.67	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.22	-$1.62	-$1.63
Total Assets	$5.36B	$4.63B	$3.72B	$3.25B	$2.37B	$2.07B	$1.73B	$1.31B	$993.15M	$817.59M	$365.09M
Total Liabilities	$1.67B	$1.38B	$1.13B	$1.02B	$660.90M	$698.50M	$608.50M	$669.10M	$512.39M	$445.45M	$50.21M
Shareholders' Equity	$3.69B	$3.25B	$2.59B	$2.23B	$1.71B	$1.37B	$1.13B	$636.90M	$480.80M	$372.14M	$314.88M
Cash & Equivalents	$332.40M	$713.00M	$233.00M	$251.10M	$262.90M	$340.80M	$187.10M	$112.30M	$141.71M	$254.71M	$83.27M
Operating Cash Flow	$898.10M	$782.70M	$595.40M	$389.90M	$339.40M	$256.50M	$228.50M	$147.00M	$101.40M	-$94.33M	-$106.18M
Capital Expenditures	$27.70M	$34.00M	$38.20M	$28.30M	$16.50M	$23.40M	$10.90M	$14.70M	$24.80M	$6.94M	$4.11M
Free Cash Flow	$870.40M	$748.70M	$557.20M	$361.60M	$322.90M	$233.10M	$217.60M	$132.30M	$76.60M	-$101.27M	-$110.29M
Share Repurchases	$66.00M	$167.70M	$300.00M	$0	$0	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	101.60M	100.10M	99.40M	98.70M	96.50M	94.90M	93.50M	92.30M	90.80M	88.79M	86.88M
Weighted Average Diluted Shares	n/a	102.50M	103.70M	101.00M	98.90M	97.90M	97.80M	95.70M	95.40M	88.09M	86.71M
EPS (Basic)	n/a	$4.81	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.23	-$1.62	-$1.63

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView